Internal Medicine, Hematology & Oncology · Anniston, AL
NPI
1548203235
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
901 Leighton Ave Ste 602
Anniston, AL, 36207
Phone (256) 238-1011
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
121,929 services
Medicare patients, 2024
513
Average age 74
Drug cost, 2024
$9.1M
1,464 prescriptions
Company payments, 2025
$1,693
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert M Conry was code J9271 (injection, pembrolizumab, 1 mg), 16,600 times for 19 patients. In total Robert M Conry billed 121,929 services in 160 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,600 | 19 | $44.73 | $743K |
| J0897 Injection, denosumab, 1 mg | Office | 7,980 | 41 | $20.49 | $163K |
| 85025 Blood Count | Office | 1,352 | 452 | $7.56 | $10K |
| 36415 Venipuncture Blood Collection | Office | 1,329 | 438 | $8.64 | $11K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,300 | 11 | $15.46 | $20K |
| 80053 Clinical Chemistry | Office | 1,266 | 446 | $10.29 | $13K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,040 | 34 | $0.09 | $91.93 |
| J1750 Injection, iron dextran, 50 mg | Office | 633 | 29 | $13.48 | $8,531 |
| 99214 Office E&M - Established | Office | 548 | 255 | $89.73 | $49K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 540 | 16 | $0.25 | $137 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 435 | 28 | $0.23 | $99.3 |
| 88185 Surgical Pathology Examination | Office | 389 | 21 | $15.98 | $6,217 |
| 96375 Injection Administration | Office | 377 | 71 | $10.57 | $3,984 |
| 96413 Chemotherapy Administration | Office | 311 | 67 | $86.12 | $27K |
| 82728 Clinical Chemistry | Office | 270 | 187 | $13.06 | $3,526 |
By year: 2022 $3.0M for 134,641 services; 2023 $4.2M for 177,984 services; 2024 $3.2M for 121,929 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,352 | 452 | $7.56 | $10K |
| 36415 Venipuncture Blood Collection | 1,329 | 438 | $8.64 | $11K |
| 80053 Clinical Chemistry | 1,266 | 446 | $10.29 | $13K |
| 88185 Surgical Pathology Examination | 389 | 21 | $15.98 | $6,217 |
| 82728 Clinical Chemistry | 270 | 187 | $13.06 | $3,526 |
| 83550 Clinical Chemistry | 268 | 187 | $8.40 | $2,252 |
| 83540 Clinical Chemistry | 268 | 187 | $6.23 | $1,671 |
| 83883 Clinical Chemistry | 182 | 50 | $13.24 | $2,409 |
| 84443 Clinical Chemistry | 156 | 51 | $16.46 | $2,568 |
| 82607 Clinical Chemistry | 140 | 119 | $14.55 | $2,037 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert M Conry prescribed most often to Medicare patients was Letrozole, with 107 prescriptions and refills. In total Robert M Conry wrote 1,464 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 107 | 260 | 37 | $2,780 |
| Prednisone Generic | 65 | 70 | 26 | $311 |
| Revlimid Lenalidomide | 62 | 62 | Under 11 | $1.1M |
| Xtandi Enzalutamide | 55 | 57 | Under 11 | $793K |
| Brukinsa Zanubrutinib | 49 | 49 | Under 11 | $522K |
| Dexamethasone Generic | 48 | 59 | 16 | $828 |
| Imbruvica Ibrutinib | 47 | 47 | Under 11 | $1.0M |
| Hydroxyurea Generic | 47 | 90 | 17 | $1,773 |
| Pomalyst Pomalidomide | 43 | 43 | Under 11 | $932K |
| Lenalidomide Generic | 43 | 43 | Under 11 | $542K |
| Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 | 40 | 40 | Under 11 | $145K |
| Jakafi Ruxolitinib Phosphate | 37 | 37 | Under 11 | $648K |
| Ondansetron Odt Ondansetron | 36 | 36 | 28 | $508 |
| Pazopanib Hcl Generic | 35 | 35 | Under 11 | $172K |
| Acyclovir Generic | 30 | 36 | Under 11 | $221 |
Brand drugs: 676 claims; generic drugs: 788 claims; opioid claims: 75.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert M Conry $1,693 ($1,693 in general payments such as food, travel and fees) from 14 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,049.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 15 | $1,049 |
| Gilead Sciences, Inc. GILD | 5 | $108 |
| Daiichi Sankyo Inc. 4568.T | 4 | $89.3 |
| Array Biopharma Inc PFE | 3 | $66.84 |
| Celgene Corporation BMY | 3 | $65.49 |
| Janssen Biotech, Inc. JNJ | 3 | $64.46 |
| Stemline Therapeutics Inc. | 2 | $52.4 |
| Merck Sharp & Dohme LLC MRK | 2 | $46.74 |
| GlaxoSmithKline, LLC. GSK | 2 | $40.44 |
| Abbvie Inc. ABBV | 2 | $34.55 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.